| |
|
| WHAT: |
In recognition of his over-fifty-year career at
the University of Pennsylvania School of Medicine,
Dr. Nowell and his colleagues from Penn and other institutions
will talk about the history of the Philadelphia chromosome and
what it portends for the next generation of cancer therapies.
The Philadelphia chromosome was first described in 1960 by Dr.
Nowell at Penn and the late David Hungerford from the Fox Chase
Cancer Center’s Institute for Cancer Research. It proved
to be the first gene-based cause for cancer. Understanding abnormalities
in the replication of the chromosome led to the eventual development
of the genetically targeted cancer drug Gleevec five years ago.
|
| WHEN: |
Wednesday, September 13, 2006
8:45 a.m. - 4:30 p.m.
|
| WHERE: |
University of Pennsylvania Museum of Archeology
3260 South St., Philadelphia, PA |
| AGENDA: |
| 8:00 am - 8:45 am |
Registration/Continental
Breakfast |
| 8:45 am - 9:15 am |
Opening remarks
Arthur Rubenstein, MBBCh, Dean of the Univeristy of Pennsylvania
School of Medicine
Peter C. Nowell, MD, Department of Pathology and Laboratory
Medicine
Mark Tykocinski, MD, Chair of the Department of Pathology
and Laboratory Medicine |
| 9:15 am - 10:00 am |
The Philadelphia Chromosome: A
discovery ahead of its time
Janet Rowley, MD, University of Chicago |
| 10:00 am - 10:45 am |
MicroRNA genes in leukemogenesis
Carlo Croce, MD, Ohio State University |
| 10:45 am - 11:00 am |
Break |
| 11:00 am - 11:45 am |
The road from the discovery of
tyrosine phosphorylation to the development of tyrosine
kinase inhibitors and beyond
Tony Hunter, PhD, Salk Institute for Biological Studies |
| 11:45 am - 1:30 pm |
Lunch |
| 1:30 pm - 1:45 pm |
Remarks
John Glick, MD, Abramson Cancer Center, Penn
Craig Thompson, MD, Abramson Cancer Center, Penn |
| 1:45 pm - 2:30 pm |
The development of targeted therapy
in the erbB system
Mark Greene, MD, PhD, FRCP, Department of Pathology and
Laboratory Medicine, Penn |
| 2:30 pm - 3:15 pm |
Stem cells and prostate cancer
Owen Witte, MD, University of California, Los Angeles |
| 3:15 pm - 3:30 pm |
Break |
| 3:30 pm - 4:15 pm |
Translation of the Philadelphia
Chromosome into therapy for CML
Brian Druker, MD, Oregon Health & Science University |
| 4:15 pm - 4:30 pm |
Program Conclusion and Evaluation
Mark Greene, MD, PhD, FRCP |
|
The symposium is sponsored by the Penn Department of Pathology
and Laboratory Medicine and is also offered as CME-certified course.
Please contact Karen Kreeger at (215) 349-5658 or karen.kreeger@uphs.upenn.edu
if you plan to attend.
###
PENN Medicine is a $2.9 billion enterprise
dedicated to the related missions of medical education, biomedical
research, and high-quality patient care. PENN Medicine consists
of the University of Pennsylvania School of Medicine (founded in
1765 as the nation's first medical school) and the University of
Pennsylvania Health System.
Penn's School of Medicine is ranked #2 in the nation for receipt
of NIH research funds; and ranked #3 in the nation in U.S. News
& World Report's most recent ranking of top research-oriented
medical schools. Supporting 1,400 fulltime faculty and 700 students,
the School of Medicine is recognized worldwide for its superior
education and training of the next generation of physician-scientists
and leaders of academic medicine.
The University of Pennsylvania Health System includes three hospitals,
all of which have received numerous national patient-care honors [Hospital
of the University of Pennsylvania; Pennsylvania Hospital, the nation's
first hospital; and Penn Presbyterian Medical Center]; a faculty practice
plan; a primary-care provider network; two multispecialty satellite
facilities; and home care and hospice. |
Feed
